CU23703A3 - RAGE FUSION PROTEINS AND METHODS OF USE - Google Patents

RAGE FUSION PROTEINS AND METHODS OF USE

Info

Publication number
CU23703A3
CU23703A3 CU20070033A CU20070033A CU23703A3 CU 23703 A3 CU23703 A3 CU 23703A3 CU 20070033 A CU20070033 A CU 20070033A CU 20070033 A CU20070033 A CU 20070033A CU 23703 A3 CU23703 A3 CU 23703A3
Authority
CU
Cuba
Prior art keywords
rage
fusion proteins
methods
rage fusion
domain
Prior art date
Application number
CU20070033A
Other languages
Spanish (es)
Inventor
Jeffrey C Webster
Ye E Tian
Robert Rothlein
Adnan M M Mjalli
Original Assignee
Trans Tech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trans Tech Pharma Inc filed Critical Trans Tech Pharma Inc
Priority to CU20070033A priority Critical patent/CU23703A3/en
Publication of CU23703A3 publication Critical patent/CU23703A3/en

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

Se describen proteínas de fusión RAGE que comprenden secuencias de polipéptidos RAGE unidas a un segundo polipéptido que no es RAGE. La proteína de fusión RAGE puede utilizar un dominio de polipéptido RAGE que comprende un sitio de unión a ligandos de RAGE y un engarce intedominio unido directamene a un dominio CH2 de inmunoglobulina. Tales proteínas de fusión pueden proporcionar unión de alta afinidad, específica a ligandos de RAGE. También se describe el uso de las proteínas de fusión RAGE como terapeúticos para las patologías mediadas por RAGE.RAGE fusion proteins comprising RAGE polypeptide sequences bound to a second non-RAGE polypeptide are described. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an intervening linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins can provide high affinity binding, specific to RAGE ligands. The use of RAGE fusion proteins as therapeutic for RAGE-mediated pathologies is also described.

CU20070033A 2007-02-02 2007-02-02 RAGE FUSION PROTEINS AND METHODS OF USE CU23703A3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CU20070033A CU23703A3 (en) 2007-02-02 2007-02-02 RAGE FUSION PROTEINS AND METHODS OF USE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20070033A CU23703A3 (en) 2007-02-02 2007-02-02 RAGE FUSION PROTEINS AND METHODS OF USE

Publications (1)

Publication Number Publication Date
CU23703A3 true CU23703A3 (en) 2011-09-21

Family

ID=44712963

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20070033A CU23703A3 (en) 2007-02-02 2007-02-02 RAGE FUSION PROTEINS AND METHODS OF USE

Country Status (1)

Country Link
CU (1) CU23703A3 (en)

Similar Documents

Publication Publication Date Title
DOP2007000089A (en) RAG FUSION PROTEINS, FORMULATIONS AND EMPLOYMENT METHODS OF THE SAME
AR059377A1 (en) RAGE FUSION PROTEINS AND METHODS OF USE
ECSP077221A (en) RPGS FUSION PROTEINS AND METHODS OF USE
ECSP077297A (en) RPGS FUSION PROTEINS AND METHODS OF USE
PE20151673A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
UY33366A (en) TYPE III FIBRONECTINE TO THE TENTH (10Fn3) OF SERIOALBUMIN UNION AND FUSION MOLECULES THAT UNDERSTAND THEM
DOP2014000083A (en) IMMUNO LINKERS AGAINST TNF
CL2011002129A1 (en) Binding proteins to il-17; construction of il-17 binding protein comprising a binding polypeptide or a constant domain of an immunoglobulin; binding protein conjugate to il-17; vector and host cell; composition for the release of a binding protein; method to reduce the activity of il-17.
UY32971A (en) PROTEINS OF UNION TO THE ANTIGEN OF HUMAN IL-23
EA200701211A1 (en) POLYPEPTIDES THAT ARE BINDING WITH BR3, AND THEIR APPLICATION
AR076655A1 (en) COMPOSITIONS AND METHODS FOR ANTIBODIES GOING TO THE COMPLEMENT PROTEIN C3B
MX2013013832A (en) Fc RECEPTOR BINDING PROTEINS.
MX357678B (en) Tdp-43 specific binding molecules.
UY31123A1 (en) NATURAL FUSION PROTEINS
BRPI0514435A (en) sequential isolation of proteins and purification schemes by affinity chromatography
MX2013015323A (en) SERPINE FUSION POLIPEPTIDES AND SAME USE METHODS.
WO2012040323A8 (en) Multimeric il-15 soluble fusion molecules and methods of making and using same
EA201100923A1 (en) HUMAN ANTIBODIES AGAINST THE TISSUE FACTOR
CO6382161A2 (en) BESPECIFIC MOLECULES OF UNION TO EGFR / IGFIR
ECSP12012272A (en) PROTEINS THAT JOIN TNF-?
CR20120105A (en) THERAPEUTIC PROTEINS OF UNION TO DLL4
CU23703A3 (en) RAGE FUSION PROTEINS AND METHODS OF USE
CU23731A3 (en) RAGE FUSION PROTEINS AND METHODS OF USE
BRPI0608300A2 (en) tyrosine kinase inhibitor compositions and methods for the manufacture and use of these compositions in the treatment of diseases
TH178622A (en) A molecule specifically bound to TDP-43.

Legal Events

Date Code Title Description
FG Grant of patent
FD Lapse (for not paying fees)